Evaluation of histogenesis of B-lymphocytes in pediatric EBV-related post-transplant lymphoproliferative disorders

Bone Marrow Transplantation

Volumn 33, Issue 3, 2004, Pages 321-327

  Abed, N ^a   Casper, J T ^a   Camitta, B M ^a   Margolis, D ^a   Trost, B ^a   Orentas, R ^a   Chang, C C ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

EBV; Histogenesis; PTLD

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; GANCICLOVIR; INTERFERON REGULATORY FACTOR 1; OKT 3; PARAFFIN; PROTEIN BCL 6; RITUXIMAB; SYNDECAN 1; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLOGENIC BONE MARROW TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; B LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL OBSERVATION; CONTROLLED STUDY; DISEASE CLASSIFICATION; EPSTEIN BARR VIRUS; EVALUATION; FEMALE; GENETIC MARKER; GERMINAL CENTER; GRAFT VERSUS HOST REACTION; HISTOGENESIS; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE DEPLETION; LYMPHOPROLIFERATIVE DISEASE; MALE; PEDIATRICS; PHENOTYPE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SCHOOL CHILD; T LYMPHOCYTE; WHOLE BODY RADIATION; WORLD HEALTH ORGANIZATION;

ADOLESCENT; B-LYMPHOCYTES; BONE MARROW TRANSPLANTATION; CHILD; DNA-BINDING PROTEINS; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GERMINAL CENTER; HEMATOLOGIC DISEASES; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON REGULATORY FACTORS; LYMPHOCYTE DEPLETION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MEMBRANE GLYCOPROTEINS; PROTEOGLYCANS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-6; SYNDECAN-1; SYNDECANS; TRANSCRIPTION FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 1342332366     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704395     Document Type: Article

References (36)

1. Harris N, Swerdlow SH, Frizzera G, Knowels DM. Post-transplant lymphoproliferative disorders. In: Jaffe E, Harris NL, Stein H, Vardiman JW (eds) The World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001, pp 264-269.
2. Knowles DM, Cesarman E, Chadburn A et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85: 552-565.
3. Ho M, Jaffe R, Miller G et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988; 45: 719-727.
4. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995; 59: 524-529.
5. Boyle GJ, Michaels MG, Webber SA et al. Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients. J Pediatr 1997; 131: 309-313.
6. Riddler SA, Breinig MC, McKnight JL. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994; 84: 972-984.
7. Rooney CM, Smith CA, Ng CY et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345: 9-13.
8. Gross TG, Steinbuch M, DeFor T et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant 1999; 23: 251-258.
9. Orazi A, Hromas RA, Neiman RS et al. Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features. Am J Clin Pathol 1997; 107: 419-429.
10. Zutter MM, Martin PJ, Sale GE et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520-529.
11. Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Posttransplant lymphoproliferative disorder: a review. Bone Marrow Transplant 2003; 31: 145-155.
12. Micallef IN, Chhanabhai M, Gascoyne RD et al. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience. Bone Marrow Transplant 1998; 22: 981-987.
13. Dhodapkar MV, Abe E, Theus A et al. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood 1998; 91: 2679-2688.
14. Carbone A, Gloghini A, Gaidano G et al. Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease. Blood 1998; 92: 2220-2228.
15. Carbone A, Gaidano G, Gloghini A et al. Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protem-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Blood 1998; 91: 747-755.
16. Sebestyen A, Berczi L, Mihalik R et al. Syndecan-1 (CD138) expression in human non-Hodgkin lymphomas. Br J Haematol 1999; 104: 412-419.
17. Sanderson RD, Lalor P, Bernfield M. B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul 1989; 1: 27-35.
18. Carey DJ. Syndecans: multifunctional cell-surface co-receptors. Biochem J 1997; 327: 1-16.
19. Kjellen L, Lindahl U. Proteoglycans: structures and interactions. Anna Rev Biochem 1991; 60: 443-475.
20. Gaidano G, Carbone A. MUM1: a step ahead toward the understanding of lymphoma histogenesis. Leukemia 2000; 14: 563-566.
21. Natkunam Y, Warnke RA, Montgomery K et al. Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol 2001; 14: 686-694.
22. Tsuboi K, Iida S, Inagaki H et al. MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia 2000; 14: 449-456.
23. Carbone A, Gloghini A, Larocca LM et al. Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood 2001; 97: 744-751.
24. Orentas RJ. Determination of Epstein-Barr virus (EBV) load by RT-PCR and cellular dilution. Mol Cell Probes 1998; 12: 427-430.
25. Keever-Taylor CA, Bredeson C, Loberiza FR et al. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. Biol Blood Marrow Transplant 2001; 7: 620-630.
26. Margolis D, Camitta B, Pietryga D et al. Unrelated donor bone marrow transplantation to treat severe aplastic anaemia in children and young adults. Br J Haematol 1996; 94: 65-72.
27. Larocca LM, Capello D, Rinelli A et al. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood 1998; 92: 1011-1019.
28. Paessler M, Kossev P, Tsai D et al. Expression of SHP-1 phosphatase indicates post-germinal center cell derivation of B-cell posttransplant lymphoproliferative disorders. Lab Invest 2002; 82: 1599-1606.
29. Rooney CM, Smith CA, Ng CY et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549-1555.
30. Yang J, Tao Q, Flinn IW et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 2000; 96: 4055-4063.
31. Shapiro RS, McClain K, Frizzera G et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71: 1234-1243.
32. Collins MH, Montone KT, Leahey AM et al. Autopsy pathology of pediatric posttransplant lymphoproliferative disorder. Pediatrics 2001; 107: E89.
33. Simon M, Bartram CR, Friedrich W et al. Fatal B-cell lymphoproliferative syndrome in allogencie marrow graft recipients. A clinical, immunobiological and pathological study. Virchows Arch B Cell Pathol Incl Mol Pathol 1991; 60: 307-319.
34. Davey DD, Kamat D, Laszewski M et al. Epstein-Barr virus-related lymphoproliferative disorders following bone marrow transplantation: an immunologic and genotypic analysis. Mod Pathol 1989; 2: 27-34.
35. Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185-1191.
36. Lones MA, Lopez-Terrada D, Shintaku IP et al. Posttransplant lymphoproliferative disorder in pediatric bone marrow transplant recipients: disseminated disease of donor origin demonstrated by fluorescence in situ hybridization. Arch Pathol Lab Med 1998; 122: 708-714.